1. Home
  2. MUX vs CELC Comparison

MUX vs CELC Comparison

Compare MUX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

HOLD

Current Price

$18.93

Market Cap

1.6B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$80.45

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUX
CELC
Founded
1979
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
4.2B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
MUX
CELC
Price
$18.93
$80.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$26.63
$112.56
AVG Volume (30 Days)
899.8K
755.4K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
168.60
N/A
EPS
0.61
N/A
Revenue
$197,553,000.00
N/A
Revenue This Year
$37.86
N/A
Revenue Next Year
$31.10
$720.19
P/E Ratio
$30.46
N/A
Revenue Growth
13.23
N/A
52 Week Low
$14.42
$44.42
52 Week High
$29.70
$151.02

Technical Indicators

Market Signals
Indicator
MUX
CELC
Relative Strength Index (RSI) 45.74 37.66
Support Level $16.62 $78.60
Resistance Level $19.09 $96.39
Average True Range (ATR) 0.72 3.55
MACD -0.25 -0.94
Stochastic Oscillator 35.71 6.33

Price Performance

Historical Comparison
MUX
CELC

About MUX McEwen Mining Inc.

McEwen Inc, formerly McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, majority of production occurs in the United States.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: